FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021331304> ?p ?o ?g. }

• W3021331304 endingPage "1207" @default.
• W3021331304 startingPage "1207" @default.
• W3021331304 abstract "Osteosarcoma is the most common form of primary bone cancer. Over 20% of osteosarcoma patients present with pulmonary metastases at diagnosis, and nearly 70% of these patients fail to respond to treatment. Previous work revealed that human and canine osteosarcoma cell lines are extremely sensitive to the therapeutic proteasome inhibitor bortezomib in vitro. However, bortezomib has proven disappointingly ineffective against solid tumors including sarcomas in animal experiments and clinical trials. Poor tumor penetration has been speculated to account for the inconsistency between in vitro and in vivo responses of solid tumors to bortezomib. Here we show that the second-generation proteasome inhibitor ixazomib, which reportedly has enhanced solid tumor penetration compared to bortezomib, is toxic to human and canine osteosarcoma cells in vitro. We used experimental osteosarcoma metastasis models to compare the efficacies of ixazomib and bortezomib against primary tumors and metastases derived from luciferase-expressing KRIB or 143B human osteosarcoma cell lines in athymic mice. Neither proteasome inhibitor reduced the growth of primary intramuscular KRIB tumors, however both drugs inhibited the growth of established pulmonary metastases created via intravenous inoculation with KRIB cells, which were significantly better vascularized than the primary tumors. Only ixazomib slowed metastases from KRIB primary tumors and inhibited the growth of 143B pulmonary and abdominal metastases, significantly enhancing the survival of mice intravenously injected with 143B cells. Taken together, these results suggest ixazomib exerts better single agent activity against osteosarcoma metastases than bortezomib. These data provide hope that incorporation of ixazomib, or other proteasome inhibitors that penetrate efficiently into solid tumors, into current regimens may improve outcomes for patients diagnosed with metastatic osteosarcoma." @default.
• W3021331304 created "2020-05-13" @default.
• W3021331304 creator A5001310483 @default.
• W3021331304 creator A5011159150 @default.
• W3021331304 creator A5046373006 @default.
• W3021331304 creator A5051367520 @default.
• W3021331304 creator A5051491316 @default.
• W3021331304 creator A5054259850 @default.
• W3021331304 creator A5075390238 @default.
• W3021331304 creator A5085046088 @default.
• W3021331304 date "2020-05-11" @default.
• W3021331304 modified "2023-10-18" @default.
• W3021331304 title "The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice" @default.
• W3021331304 cites W1556426431 @default.
• W3021331304 cites W1898544704 @default.
• W3021331304 cites W1912023462 @default.
• W3021331304 cites W1969214285 @default.
• W3021331304 cites W1973547516 @default.
• W3021331304 cites W1975724263 @default.
• W3021331304 cites W1984448141 @default.
• W3021331304 cites W1988325237 @default.
• W3021331304 cites W1993267562 @default.
• W3021331304 cites W1997278471 @default.
• W3021331304 cites W1999260523 @default.
• W3021331304 cites W2000044224 @default.
• W3021331304 cites W2004252053 @default.
• W3021331304 cites W2004254194 @default.
• W3021331304 cites W2009058293 @default.
• W3021331304 cites W2013881151 @default.
• W3021331304 cites W2014931987 @default.
• W3021331304 cites W2030471654 @default.
• W3021331304 cites W2032481064 @default.
• W3021331304 cites W2037132614 @default.
• W3021331304 cites W2062789329 @default.
• W3021331304 cites W2067767807 @default.
• W3021331304 cites W2068551729 @default.
• W3021331304 cites W2076624423 @default.
• W3021331304 cites W2078789226 @default.
• W3021331304 cites W2078950332 @default.
• W3021331304 cites W2087738968 @default.
• W3021331304 cites W2101522258 @default.
• W3021331304 cites W2109294408 @default.
• W3021331304 cites W2109371953 @default.
• W3021331304 cites W2118783447 @default.
• W3021331304 cites W2122937570 @default.
• W3021331304 cites W2123745849 @default.
• W3021331304 cites W2124560610 @default.
• W3021331304 cites W2126008131 @default.
• W3021331304 cites W2135201636 @default.
• W3021331304 cites W2135947783 @default.
• W3021331304 cites W2136399690 @default.
• W3021331304 cites W2147059616 @default.
• W3021331304 cites W2150946410 @default.
• W3021331304 cites W2155896109 @default.
• W3021331304 cites W2159137646 @default.
• W3021331304 cites W2166350458 @default.
• W3021331304 cites W2170220752 @default.
• W3021331304 cites W2305290252 @default.
• W3021331304 cites W2310758743 @default.
• W3021331304 cites W2316206479 @default.
• W3021331304 cites W2343196968 @default.
• W3021331304 cites W2401985466 @default.
• W3021331304 cites W2513951655 @default.
• W3021331304 cites W2550186707 @default.
• W3021331304 cites W2560083147 @default.
• W3021331304 cites W2561848201 @default.
• W3021331304 cites W2580091136 @default.
• W3021331304 cites W2583934405 @default.
• W3021331304 cites W2586636788 @default.
• W3021331304 cites W2600572285 @default.
• W3021331304 cites W2607270289 @default.
• W3021331304 cites W2615030896 @default.
• W3021331304 cites W2616195722 @default.
• W3021331304 cites W2748924884 @default.
• W3021331304 cites W2757019415 @default.
• W3021331304 cites W2767053399 @default.
• W3021331304 cites W2768999031 @default.
• W3021331304 cites W2770803466 @default.
• W3021331304 cites W2790902804 @default.
• W3021331304 cites W2820126454 @default.
• W3021331304 cites W2887253292 @default.
• W3021331304 cites W2891375440 @default.
• W3021331304 cites W2901300056 @default.
• W3021331304 cites W2972932003 @default.
• W3021331304 cites W2981984335 @default.
• W3021331304 cites W3000961023 @default.
• W3021331304 cites W3003574401 @default.
• W3021331304 cites W3025580318 @default.
• W3021331304 cites W366249503 @default.
• W3021331304 doi "https://doi.org/10.3390/cancers12051207" @default.
• W3021331304 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7281181" @default.
• W3021331304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32403415" @default.
• W3021331304 hasPublicationYear "2020" @default.
• W3021331304 type Work @default.
• W3021331304 sameAs 3021331304 @default.
• W3021331304 citedByCount "9" @default.
• W3021331304 countsByYear W30213313042020 @default.
• W3021331304 countsByYear W30213313042021 @default.

• next